Medidata Solutions stock has a beautiful rising large players volume plot while the stock does a double bottom test. The speed up of FDA approvals in order to lower drug prices should benefit this company.
Medidata Solutions stock has surging large players volume on a bullish hammer candlestick.
Continue reading “Medidata Solutions Stock Surging Large Players Volume On Bullish Hammer”
Aeterna Zentaris stock is a short-term play on the PDUFA date of December 30, 2017. The gambit is that the company will get FDA approval of Macrilen.
Aeterna Zentaris stock has rising large players volume as the PDUFA date of December 30, 2017 fast approaches.
Continue reading “Aeterna Zentaris Rising Large Players Volume On PDUFA Play”
Allergan stock is a turnaround gambit on the stock being crushed over fears of a Botox competitor. Large players volume is rising and the Twiggs Money Flow just went positive.
Allergan stock is curling up on rising large players volume. The Twiggs Money Flow just gave a buy signal too.
Continue reading “Allergan Stock Curling Up On Rising Large Players Volume”
pSivida stock has a good looking Symmetrical Triangle consolidation pattern. The Twiggs Money Flow has been rising into the consolidation pattern which could suggest a breakout is coming.
pSivida stock has a rising Twiggs Money Flow while the stock trades in a Symmetrical Triangle pattern.
There are no Sell ratings, no Hold ratings, and 6 Buy ratings on pSivida stock. The average price target is $8 which represents 577.97% upside from the current price.
Continue reading “pSivida Stock Symmetrical Triangle Setup On Rising Twiggs Money Flow”
Sarepta Therapeutics could get European marketing approval for Exondys 51 at any time which will boost sales. Meanwhile, the company has great growth and is advancing other drugs through its pipeline.
Sarepta Therapeutics stock continues in a strong uptrend on Exondys 51.
Sarepta Therapeutics reported its last quarterly earnings data on October 25, 2017. The company reported EPS of ($0.20) versus the ($0.86) estimate. Revenue also beat coming in at $45.95 million versus the $41.29 million estimate.
Continue reading “Sarepta Therapeutics In Strong Uptrend From Exondys 51”
Adamis Pharmaceuticals is looking at various licensing partners for its FDA approved Symjepi which will compete against Mylan’s EpiPen. As soon as the company announces a licensing partner, this stock could explode over 130 percent higher.
Adamis Pharmaceuticals was given a $10 price target by analysts at B. Riley last week. B. Riley has a Buy rating on the stock. Overall, the stock has no Sell ratings and 3 Buy ratings. The average target price is $10 which represents 138% upside from the current price of $4.20.
Continue reading “Adamis Pharmaceuticals Could Explode Over 130 Percent”
Deciphera Pharmaceuticals will likely be pumped by the IPO underwriters soon now that the quiet period has ended.
Deciphera Pharmaceuticals’ quiet period ended on Tuesday, November 7, 2017. The brokerages that served as underwriters are working on research reports and will likely release those reports and analyst ratings on this company soon. In other words, the pump of this stock should start any week now. Please review this lesson on institutional traders and market makers.
Continue reading “Deciphera Pharmaceuticals Quiet Period Ended This Week”
With impressive beats on earnings and revenue, DENTSPLY SIRONA is a stock to add to your watch list on the next retracement.
DENTSPLY SIRONA has rising large players volume and earnings and revenue beats. DENTSPLY SIRONA reported its quarterly earnings on Friday, November 3, 2017. The company reported EPS of $0.70 versus the estimate of $0.66. Revenue also beat coming in at $1.01 billion versus the $978.99 million estimate. Revenue was up 5.8% year-over-year.
Continue reading “DENTSPLY SIRONA Rising Large Players Volume On Beats and Upgrade”
Intercept Pharmaceuticals stock sold off on an FDA warning letter at the end of the quarter. Since, large players volume has been rising while the stock has formed a basing pattern.
Intercept Pharmaceuticals has rising large players volume while the stock has formed a basing pattern. This is a very bullish technical setup.
Continue reading “Intercept Pharmaceuticals Rising Large Players Volume”
While Bluebird Bio stock doesn’t look like a good entry right now, they are advancing a CAR T treatment that looks extremely promising.
Bluebird Bio stock is in a strong uptrend as the number of analysts with Buy ratings surge.
BTIG upgraded Bluebird Bio stock from Neutral to Buy, and set a price target of $177. BTIG thinks that positive signals are coming from the FDA concerning bluebird bio’s latest CAR-T therapy for advanced stage multiple myeloma patients. Earlier this year, bluebird bio’s precursor to bb21217, named bb2121, delivered a 100% response rate among 15 multiple myeloma patients.
Continue reading “Bluebird Bio Stock Strong Uptrend On Buy Ratings”